ACSChemNeurosci
@ACSChemNeurosci
Followers
4K
Following
549
Media
321
Statuses
2K
This account is no longer active or monitored. For updates about ACS Chemical Neuroscience, follow @ACSPublications and @ACSBioMed.
Washington, DC
Joined August 2009
This account will no longer be active or monitored. We welcome our community to follow @ACSPublications or sign up for e-Alerts for future updates from ACS Chemical Neuroscience:
0
0
1
Don't miss out on this exciting discussion! This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy Read the latest research ➡ https://t.co/8SGqAqQUvS
0
0
0
Next week is World #AntimicrobialResistance Awareness Week! Join us for a webinar discussing the cutting edge work being done to fight multi-drug resistant bacteria. 🦠 📅 Wed Nov 20, 11am EST. Register here ➡�� https://t.co/0kTIScijga
0
8
14
Check out our recent works on Chronic pain published @ACSChemNeurosci A great collaboration between @DarrenDerksen lab and @zymedyne Many thanks to @MitacsCanada for the funding!
I'm not sure how many people are still on this site but I am happy to share our newest collaborative work published in ACS Chem Neursci with Zymedyne and funded by MITACS. Huge thanks to @ketspatel10 for his hard work on this project! https://t.co/d4fcXMr7Fv
0
2
11
Don't miss out on this exciting discussion! This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy Read the latest research ➡ https://t.co/wmjYLLUvGX
1
0
0
Curious about the latest research on MDMA treatments? Check out our recent collection of articles on the subject ➡ https://t.co/nt9M4h15ty
The psychedelic treatment, for PTSD, was rejected last week by government regulators.
0
0
0
❗ LAST CALL! Call for Papers: ACS Pharmacology and Translational Science invites submissions for a Virtual Special Issue on new perspectives and advances in translational #pain research to treat pain. Submit papers by August 1, 2024 ➡ https://t.co/b1ckrTbQOS
0
1
4
I am proud to have collaborated with @cahhcardi et al in this amazing paper now published in @ACSChemNeurosci. Link: https://t.co/yBz31czQLs
@Ariel_Lab
0
2
5
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ https://t.co/r3t26W1ZWN
0
0
1
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ https://t.co/yjAGOUF5g8
0
0
1
Read our latest review on the gut-microbiome brain axis in Parkinson’s disease and role of “biotics” approach #neuroscience #gutmicrobiota @ACSChemNeurosci
pubs.acs.org
Parkinson’s disease, a classical motor disorder affecting the dopaminergic system of the brain, has been as a disease of the brain, but this classical notion has now been viewed differently as the...
0
1
4
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy Read the latest research ➡ https://t.co/PiwSg7FvIJ
0
2
4
#research Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition (Friedecký, @konvalinka_jan) - @ACSChemNeurosci: https://t.co/5wm8N4y9Up
@FriedeckyGroup @IOCBPrague @CzechAcademy @UPOlomouc
pubs.acs.org
Glutamate carboxypeptidase II (GCPII, also known as PSMA or FOLH1) is responsible for the cleavage of N-acetyl-aspartyl-glutamate (NAAG) to N-acetyl-aspartate and glutamate in the central nervous...
0
4
10
To sum up today's adcomm: While the experts saw potential in the use of MDMA-assisted therapy in the treatment of PTSD, there were too many confounding variables and possible safety concerns to push for approval #Lykos
2
1
2
FDA Advisory Committee votes against recommending Lykos' #MDMA treatment for PTSD Read our latest MDMA research here ➡ https://t.co/iFVKFwAa7U
0
2
3
@jmhooker @zenbrainest want to kick off the discussion?
1
0
0
Fascinating discussions online today surrounding the FDA's consideration of a new #MDMA treatment for PTSD 🤔 When is a double-blinded study not enough? How can you blind for a treatment that includes such pronounced and well-known effects? Let us know what you think! ⬇
1
4
4
📢New collection of #ACSChemNeuro research as the FDA is expected to announce a decision on a new treatment involving #MDMA today ⏰ Read the latest research ➡ https://t.co/MiFPxVyOnt
0
4
6
It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci! We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪 🧵 https://t.co/yq4EPZPvyZ
pubs.acs.org
Synthetic cannabinoid receptor agonists (SCRAs) are a growing class of new psychoactive substances (NPS) commonly derived from an N-alkylated indole, indazole, or 7-azaindole scaffold. Diversificat...
1
4
14
This study builds on our @ACSChemNeurosci paper last year, where @PashaDavoudian mapped c-Fos response in the brain after psilocybin or ketamine, identifying the list of shared and distinct brain regions impacted by the drugs https://t.co/dyi5CWqLoZ
pubs.acs.org
Psilocybin is a psychedelic with therapeutic potential. While there is growing evidence that psilocybin exerts its beneficial effects through enhancing neural plasticity, the exact brain regions...
1
2
6